Allogeneic transplantation: A therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia

P. Mittal, R. M. Saliba, S. A. Giralt, M. Shahjahan, A. I. Cohen, S. Karandish, F. Onida, M. Beran, R. E. Champlin, M. de Lima

Research output: Contribution to journalArticle

Abstract

The role of allogeneic transplantation for myeloproliferative diseases other than chronic myeloid leukemia is not well established. In all, 20 patients with a median age of 51 years underwent allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis (n = 5), chronic myelomonocytic leukemia (CMML) (n = 8) and Philadelphia (Ph) chromosome-negative/BCR-ABL-negative chronic myeloid leukemia (CML) (n = 7) in our institution. Patients who developed acute leukemia prior to HSCT were excluded from this analysis. A total of 15 patients received related and five patients received unrelated donor transplants. One patient failed to engraft. After a median follow-up of 17.5 months, actuarial survival at 2 years was 47% (95% CI 2%-67%), and disease-free survival 37% (95% CI 17-58%). Allogeneic transplantation may provide a therapeutic option for patients with myelofibrosis, CMML and Ph chromosome-negative/BCR-ABL-negative CML.

Original languageEnglish
Pages (from-to)1005-1009
Number of pages5
JournalBone Marrow Transplantation
Volume33
Issue number10
DOIs
Publication statusPublished - May 2004

Keywords

  • Chronic myelomonocytic leukemia
  • CML
  • Myelofibrosis
  • Myeloproliferative diseases
  • Philadelphia chromosome/BCR-ABL negative

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Allogeneic transplantation: A therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia'. Together they form a unique fingerprint.

  • Cite this